On March 25, 2025 AbCellera (Nasdaq: ABCL) reported an upcoming poster presentation that includes preclinical in vivo data on its PSMA x CD3 T-cell engagers at the American Association for Cancer Research (AACR) (Free AACR Whitepaper)Ⓡ (AACR) (Free AACR Whitepaper) 116th Annual Meeting, to be held April 25 to 30 at the McCormick Place Convention Center in Chicago, Illinois (Press release, AbCellera, MAR 25, 2025, View Source [SID1234651443]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on AbCellera’s poster presentation at AACR (Free AACR Whitepaper) are as follows:

Title: PSMA x CD3 T-cell engagers show preclinical efficacy for the treatment of prostate cancer
Abstract Number: 6012
Session: Therapeutic Antibodies, Including Engineered Antibodies 2
Date and Time: Tuesday, April 29, from 2:00 p.m. to 5:00 p.m. CDT
Location: Section 35, Board 7